Clinical Trials on Lid Margin Blood Flow Density in Belgium

Total 74 results

Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

Canada, Switzerland, United States, France, Spain, Germany, Belgium, Austria, Italy, United Kingdom, Puerto Rico, Portugal
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
Avexa

Terminated

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

HIV Infections

Canada, United States, Australia, United Kingdom, Thailand, Germany, Italy, Israel, Belgium, Puerto Rico, Peru
ViiV Healthcare

Active, not recruiting

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF (EYEWITNESS)

HIV Infections | HIV

Netherlands, Germany, Mexico, Spain, United States, Belgium, Portugal, Canada, United Kingdom, Italy, Austria, France
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
ViiV Healthcare
GlaxoSmithKline

Completed

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
Abbott

Completed

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections

United States, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland, Taiwan, United Kingdom
GlaxoSmithKline

Completed

KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects (ASSERT)

HIV Infection | Infection, Human Immunodeficiency Virus I

Germany, Belgium, United Kingdom, Spain, Ireland, Italy, France, Austria, Denmark, Netherlands, Switzerland, Portugal, Latvia
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Expanded Access Study (DEAP)

HIV Infections | Infection, Human Immunodeficiency Virus

France, Germany, United States, Canada, Belgium, Austria, Brazil, Italy, Poland
ViiV Healthcare

Completed

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
ViiV Healthcare
Pfizer

Completed

Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM)

Human Immunodeficiency Virus

United States, Canada, Spain, Belgium, France, United Kingdom, Italy, Brazil, Puerto Rico, Germany, Greece
Boehringer Ingelheim

Approved for marketing

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

HIV Infections

United States, Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom
GlaxoSmithKline

Completed

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Belgium, France, Germany, Spain, Canada, Italy, Portugal, Romania, Austria, Switzerland, Poland, Latvia, Luxembourg
AbbVie

Recruiting

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Human Immuno-deficiency Virus (HIV) Disease

United States, Puerto Rico, Japan, Spain, Germany, Canada, Belgium, France, Poland, South Africa, Italy
ViiV Healthcare

Terminated

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

United States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
University of Minnesota
National Health and Medical Research Council, Australia; Bristol-Myers Squibb; National Institutes of Health Clinical Center (CC) and other collaborators

Completed

Strategic Timing of Antiretroviral Treatment (START)

HIV Infection

Spain, United States, United Kingdom, Ireland, Australia, Argentina, Denmark, Sweden, Israel, Switzerland, Germany, Brazil, Norway, Chile, Thailand, Peru, Portugal, Greece, Luxembourg, Uganda, Austria, Belgium, Czechia, Estonia, Finland, ... and more
ViiV Healthcare
GlaxoSmithKline

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
GlaxoSmithKline

Terminated

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures (ELEVATE)

Liver Diseases | HIV Infection | Thrombocytopenia | Hepatitis C Virus | HBV | NASH - Nonalcoholic Steatohepatitis | Human Immunodeficiency Virus | Chronic Liver Disease | HCV | Non-alcoholic Steatohepatitis | Hepatitis B Virus

United States, Spain, Taiwan, Italy, Belgium, France, Korea, Republic of, Canada, Russian Federation, Pakistan, Poland, India, Argentina

Clinical Trials on Lid Margin Blood Flow Density in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations